LinkedIn Image

Expert PracticeSM in Chronic Lymphocytic Leukemia: A Deep Dive Into the Disease

Meeting Overview

We are pleased to invite you to the Expert PracticeSM in Chronic Lymphocytic Leukemia: A Deep Dive Into the Disease meeting in Barcelona, Spain, on Saturday, 22 April 2017.

During this interactive, case-based meeting, leaders in the field will discuss clinical challenges in chronic lymphocytic leukemia (CLL). The program will begin with an in-depth discussion of CLL tumor biology and risk assessment. From there, patient cases will be presented and discussed followed by didactic presentations focusing on the details of each case. Finally, the appropriate management of adverse events will be discussed. Audience members will have the opportunity throughout the meeting to ask questions and participate in discussions with expert faculty.


08.00 Breakfast
08.30 Welcome and introduction
John Gribben, MD, DSc, FRCP, FRCPath, FMedSci, and prIME Oncology Medical Director
08.35 Test your knowledge of CLL
John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
08.45 Getting our feet wet: Understanding the tumor biology and genomic heterogeneity of CLL
John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
09.20 Prognosis and risk assessment in CLL: Are we making progress or just treading water?
Véronique Leblond, MD
09.55 Coffee break
10.10 Case #1—Diving in: Selecting initial therapy for a fit patient with CLL
Jennifer R. Brown, MD, PhD
10.50 Case #2—Charting a course: Critical decisions in the front-line management of elderly patients with CLL
Peter Hillmen, MBChB, FRCP, FRCPath, PhD
11.30 Lunch
12.30 Case #3—Making waves: Expanding options for the treatment of relapsed/refractory CLL
Barbara Eichhorst, MD
13.10 Case #4—Turning the tide: Addressing drug resistance in CLL
Anders Österborg, MD, PhD
13.50 Shifting sand: The evolving role for allogeneic stem cell transplantation in CLL
John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
14.25 Coffee break
14.40 Case #5—Safety is key: Management of adverse events in patients with CLL
Anders Österborg, MD, PhD
15.20 Watching the horizon: What can we expect in the coming year?
Barbara Eichhorst, MD
15.55 Test your knowledge of CLL
John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
16.00 prIME Points™


  • John Gribben, MD, DSc, FRCP, FRCPath, FMedSciBarts Cancer Institute
    London, United Kingdom
  • Jennifer R. Brown, MD, PhDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Barbara Eichhorst, MD, PhDUniversity Hospital Cologne
    Cologne, Germany
  • Peter Hillmen, MBChB, FRCP, FRCPath, PhDSt James's University Hospital
    Leeds, United Kingdom
  • Véronique Leblond, MDHôpital Pitié Salpêtrière
    Paris, France
  • Anders Österborg, MD, PhDKarolinska University Hospital
    Stockholm, Sweden

Target Audience

This activity is intended for European medical oncologists, hematologists, and other healthcare professionals involved in the management of CLL.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Describe key features of CLL tumor biology and genomic heterogeneity
  • Identify best practices for risk assessment and prognostication for patients with CLL
  • Select optimal therapy for patients with newly diagnosed CLL
  • Distinguish initial treatment options that are appropriate for frail or elderly patients with CLL
  • Incorporate emerging therapies for management of relapsed/refractory CLL
  • Identify patients who are likely to benefit from allogeneic stem cell transplantation
  • Recognize key adverse events associated with available and novel therapies for CLL, as well as strategies to manage toxicity



Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Register Now

To apply for a travel grant, click on the Register Now button.

Date and Location

Saturday, 22 April 2017
08.30 – 16.00

A reception followed by buffet dinner will be held the evening before the program on Friday, 21 April, at 19.30.

Hotel SB Diagonal Zero Barcelona
Plaça Llevant, s/n
Barcelona, Spain

Printed Materials

Printed Materials


This activity is provided by prIME Oncology.


This program is funded in part via an independent grant from AbbVie.

Continuing Education

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


prIME Oncology complies with all EFPIA Disclosure Code reporting requirements.